XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Collaborative Agreements (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Jun. 10, 2022
USD ($)
Aug. 05, 2019
USD ($)
shares
Jun. 30, 2019
USD ($)
shares
Sep. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 25, 2017
USD ($)
Aug. 15, 2017
USD ($)
Aug. 31, 2016
USD ($)
Aug. 31, 2016
TWD ($)
Jul. 27, 2016
USD ($)
Dec. 24, 2018
USD ($)
$ / shares
$ / shares
shares
Dec. 31, 2015
USD ($)
Mar. 31, 2024
USD ($)
$ / shares
Dec. 31, 2018
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2015
TWD ($)
Dec. 31, 2023
USD ($)
$ / shares
Feb. 23, 2023
shares
Jul. 01, 2022
Collaborative Agreements [Line Items]                                      
Milestone payments royalty percentage                         12.00%            
Collaboration revenue                               $ 50,000,000      
Cash equivalent                       $ 1,640,000     $ 1,640,000        
Value of new shares issued [1]                         $ 10,698       $ 7,940    
Common stock price (in New Dollars per share) | $ / shares                     $ 50                
Common stock per share price (in Dollars per share) | $ / shares                     $ 1.64   $ 0.001       $ 0.001    
Equity method long term investment (in Shares) | shares                     1,530,000                
Recognized investment loss                           $ 549          
Service agreement eligibility amount $ 3,000,000                                    
Milestone regulatory payment amount period 3 years                                    
Loan amount                         $ 1,000,000            
Percentage of working capital convertible loan                         5.00%            
Fixed conversion price equal (in Dollars per share) | $ / shares                         $ 1            
Shares issued (in Shares) | shares                                   5,291,667  
BioLite Taiwan [Member]                                      
Collaborative Agreements [Line Items]                                      
Collaboration revenue                             50,000,000        
Cash equivalent                       1,640,000     1,640,000        
BHK Co-Development Agreement [Member]                                      
Collaborative Agreements [Line Items]                                      
Milestone payment                 $ 31,649,000 $ 10,000,000                  
Description of payment settlement                         ●Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment ●Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment ●At the completion of first phase II clinical trial: $1 million, or 10% of total payment ●At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment ●Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment            
Upfront cash payment                       $ 1,000,000     $ 1,000,000        
Data and development percentage                       10.00%              
Total cash amount               $ 1,000,000       $ 10,000,000              
Co-Dev Agreement [Member]                                      
Collaborative Agreements [Line Items]                                      
Data and development percentage                         50.00%            
Cash amount             $ 3,000,000                        
Addition cash payment                         $ 3,000,000            
Additional paid-in capital         $ 3,000,000                            
Cash received         450,000                            
Rgene Corporation [Member]                                      
Collaborative Agreements [Line Items]                                      
Value of new shares issued                     $ 2,550,000                
Collaborative Agreement [Member]                                      
Collaborative Agreements [Line Items]                                      
Data and development percentage                         50.00%            
Total cash amount       $ 3,000,000                              
Cash amount                         $ 3,000,000            
Licensing rights           $ 3,000,000                          
Research and development expense         $ 3,000,000                            
BioFirst Corporation Purchase Agreement [Member]                                      
Collaborative Agreements [Line Items]                                      
Shares issued (in Shares) | shares   414,702 428,571                                
Common stock consideration   $ 2,902,911 $ 3,000,000                                
Rgene Corporation [Member]                                      
Collaborative Agreements [Line Items]                                      
Ownership percentage                         26.65%       26.65%    
Ownership percentage                                     12.80%
Rgene Corporation [Member] | Service Agreements [Member]                                      
Collaborative Agreements [Line Items]                                      
Ownership percentage                         31.62%            
Rgene Corporation [Member] | Co-Dev Agreement [Member]                                      
Collaborative Agreements [Line Items]                                      
Ownership percentage                         6.40%            
Rgene Studies [Member]                                      
Collaborative Agreements [Line Items]                                      
Ownership percentage                         20.00%            
[1] Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.